As a member of the National Cancer Institute (NCI) Cooperative Group System, the Gerald J. Glasser Brain Tumor Center offers patients hope through a robust clinical trial research program.
Learn more about the trials we're participating in and how researchers are working to discover the next generation of brain tumor treatments.
For Newly-Diagnosed Patients
Immunotherapy and Radiation Therapy for Newly Diagnosed Glioblastoma
Designed for patients who are newly diagnosed with MGMT-unmethylated glioblastoma, this phase II/III study tests the use of immunotherapy drugs ipilimumab and nivolumab – which may help the body’s immune system attack cancer cells – in conjunction with radiation therapy.
For Patients with Recurrent Glioblastoma
Immunotherapy for Recurrent Glioblastoma
This phase II study examines immunotherapy drugs ipilimumab and nivolumab in patients with glioblastoma that has recurred and carries a high number of mutations. These immunotherapy medications with monoclonal antibodies may help the body's immune system attack cancerous cells and may interfere with tumor cells’ ability to grow and spread.
Genetic-Guided Treatment for Brain Metastases
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. These brain metastases often have altered or mutated genes. Medications that target these genes may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Neuroscience Research and Clinical Trials
Atlantic Health System Neuroscience participates in dozens of clinical trials each year, giving our patients access to the latest technology and medications sooner than available to the general public. Our neurological researchers frequently present their findings from these studies at key medical meetings around the globe.